All In Biotech

Drug Trial Radar · NCT05456828

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

A Multi-Center, Open-label, Single Ascending-Dose and Multiple Ascending-Dose Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASKG712 Following Intravitreal Administration in Patients With Neovascular Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Feb 10, 2023

Primary completion

Nov 3, 2025

Study completion Nov 3, 2025

Sponsor

Lead sponsor
Visara, Inc.Industry
Sponsor type
Industry
Collaborators
Suzhou Aosaikang Biopharmaceutical Co., Ltd.; AskGene Pharma, Inc.
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the Phase 1/2a study is comprised of single ascending-dose component (Part 1), multiple ascending-dose component (Part 2) and multiple-dose extension component (Part 3) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in patients with neovascular age-related macular degeneration (nAMD).

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • ASKG712Biological

    ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular adverse events (AEs) of the study eyesTime frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks
  2. Incidence of non-ocular adverse events (AEs)Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.